IMARA
Imara Inc. is a clinical-stage biotechnology company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin. Imara is currently advancing IMR-687, a highly selective, potent small molecule inhibitor of PDE9 that is an oral, once-a-day, potentially disease-modifying treatment for sickle cell disease and beta-thalassemia. IMR-687 is being designed to have a multimodal mechanism of action that acts on red blood cells, white blood cells, adhesion mediators and other cell types.
IMARA
Industry:
Biopharma Biotechnology Genetics Health Care Therapeutics
Founded:
2015-01-01
Address:
Cambridge, Massachusetts, United States
Country:
United States
Website Url:
http://www.imaratx.com
Total Employee:
11+
Status:
Active
Contact:
617 231-6021
Total Funding:
144.8 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics WordPress Google Universal Analytics Font Awesome Apache
Similar Organizations
Acrivon Therapeutics
Acrivon Therapeutics is a precision oncology therapeutics company specializing in drug development through early clinical treatment success.
Adendra Therapeutics
Adendra Therapeutics wants to use new insights into dendritic cell biology to develop a novel type of immunotherapy.
Alector
Alector is combining state-of-the-art antibody technology and recent discoveries in neuroimmunology and human genetics to develop novel.
Apostle
Apostle Inc is a provider of innovative technologies and services for public health and life sciences.
Arvinas
Arvinas advances therapies degrading disease-causing proteins for life-threatening diseases, from discovery to commercialization.
Biochip Labs
Biochip Labs provides blood disorder testing for conditions like sickle cell disease and thalassemia.
Biognosys
Biognosys provides the best possible solutions to support researchers in their protein analysis needs.
Celsius Therapeutics
Celsius Therapeutics is a biotechnology company that develops precision medicines for cancer and autoimmune disease patients.
Cleave Therapeutics
Cleave Therapeutics is focused on protein homeostasis and stress pathways in cancer and neurodegeneration.
Cystetic Medicines
Cystetic Medicines develops a treatment that potentially could help people with cystic fibrosis (CF), regardless of genetic mutation.
Kinnate Biopharma
Kinnate Biopharma develops precision oncology therapeutics to treat patients with genomically-defined cancers.
LiVeritas Biosciences
Committed to Truth-telling for Early Success in Drug Development
Loxo Oncology
Loxo Oncology is a biopharmaceutical company focused on targeted cancer therapies for genetically-defined patient populations.
MiaDNA
MiaDNA provides people with the genetic information they need to improve their lifestyle and living habits.
NanoMosaic
NanoMosaic provides solutions for early illness detection, prognostic monitoring, and biomarker identification.
Nimbus Therapeutics
Nimbus Discovery is now Nimbus Therapeutics to reflect our transition into a clinical stage company.
NonExomics
NonExomics develops therapeutics to diagnose and cure diseases emanating from the nonexome.
OncoResponse
OncoResponse is a company providing cancer research into immunotherapies and the newest technologies for oncologists.
QUE Oncology
QUE Oncology develops novel therapies to address unmet medical needs in the treatment of cancer and its consequences.
Refuge Biotechnologies
Refuge Biotechnologies therapeutic company focused on gene editing and genetic engineering of immune cells for cancer immunotherapy.
REGENXBIO
REGENXBIO develops adeno-associated viral vector-based therapeutics and research tools, offering NAV, a recombinant AAV-vector.
Swing Therapeutics
Swing Therapeutics provides digital therapeutics for people with chronic conditions.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Rock Springs Capital
Rock Springs Capital investment in Series B - Imara
Bay City Capital
Bay City Capital investment in Series B - Imara
OrbiMed
OrbiMed investment in Series B - Imara
RA Capital Management
RA Capital Management investment in Series B - Imara
Arix Bioscience
Arix Bioscience investment in Series B - Imara
New Enterprise Associates
New Enterprise Associates investment in Series B - Imara
Alexandria Venture Investments
Alexandria Venture Investments investment in Series B - Imara
Lundbeckfonden Ventures
Lundbeckfonden Ventures investment in Series B - Imara
Pfizer Venture Investments
Pfizer Venture Investments investment in Series B - Imara
Bay City Capital
Bay City Capital investment in Series A - Imara
Official Site Inspections
http://www.imaratx.com Semrush global rank: 4.29 M Semrush visits lastest month: 2.68 K
- Host name: 104.21.46.239
- IP address: 104.21.46.239
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Imara"
Imara - Crunchbase Company Profile & Funding
Contact Email [email protected] Phone Number 617 231-6021 Imara Inc. is a clinical-stage biotechnology company dedicated to developing and commercializing novel therapeutics to …See details»
Enliven Therapeutics and Imara Announce Merger Agreement
Oct 13, 2022 Merger to create Nasdaq-listed, clinical-stage biopharmaceutical company focused on advancing Enliven’s portfolio of precision oncology programsCombined company is …See details»
Imara Announces IMR-687 Granted Fast Track Designation and …
Jul 30, 2020 For more information, please visit www.imaratx.com.Cautionary Note Regarding Forward-Looking StatementsStatements in this press release about future expectations, plans …See details»
Imara Announces Stockholder Approval of Merger With Enliven
Feb 22, 2023 Imara, Inc.-- Combined Company to Trade on Nasdaq Under Ticker “ELVN” ---- Imara Announces 1-for-4 Reverse Stock Split of Common Stock -- BROOKLINE, Mass., Feb. …See details»
Imara Company Profile - Office Locations, Competitors, Revenue
Feb 27, 2023 Imara is a company, dedicated to developing novel therapeutics for people living with sickle cell disease and other hemoglobinopathies. The Company offers IMR-687, an oral, …See details»
Imara | VentureRadar
Website: http://www.imaratx.com/ Develops novel therapeutics for sickle cell disease and hemoglobinopathies, including IMR-687, a potent small molecule inhibitor of ...See details»
Imara Announces Pricing of Public Offering - Nasdaq
Jul 14, 2021 Investor Contact: Michael Gray 617-835-4061 [email protected]. Imara, Inc. In This Story IMRA. Market Makers.See details»
IMARA Inc. - Cruelty Free Investing
Company Website: https://imaratx.com Contact: [email protected] ©2024 CrueltyFreeInvesting.org | Cruelty Free Investing is a registered 501c3 Non-Profit Organization …See details»
Enliven Therapeutics and Imara Announce Merger Agreement
Oct 13, 2022 A live webcast of the presentation will be available on the Events & Presentations section of Imara’s website at https://imaratx.com. A replay of the webcast will be archived on …See details»
Imara Announces Appointment of Laura A. Williams, M.D., MPH
Jun 30, 2021 For more information, please visit www.imaratx.com. Cautionary Note Regarding Forward-Looking Statements Statements in this press release about future expectations, plans …See details»
Imara to Participate in Upcoming Investor Conferences
Sep 15, 2021 For more information, please visit www.imaratx.com. Media Contact: Marin Bergman Ten Bridge Communications 818-516-2746 [email protected]. …See details»
Imara Announces Appointment of Stephen M. Migausky as …
May 4, 2020 Imara Inc. (IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare …See details»
Imara TX Application Manager
Example: Funds may support programs and other activities conducted by the organization. -----Additional Information on Imara Advocacy. Real Impact Awards FAQs. Grantor Contact …See details»
Imara Reports Full Year 2021 Financial Results and Business
Mar 15, 2022 The live webcast will be available under “Events and Presentations” in the Investors section of the Company’s website at imaratx.com. The conference call can be …See details»
Imara to Present Clinical Data on IMR-687 as Monotherapy and in ...
BOSTON, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics …See details»
Imara Announces Results of Interim Analyses of Tovinontrine
Apr 5, 2022 For more information, please visit www.imaratx.com. Cautionary Note Regarding Forward-Looking Statements Statements in this press release about future expectations, plans …See details»
Imara - VentureRadar
Open PageRank: 8,156,814 | imaratx.com. VentureRadar Popularity. High. VentureRadar Popularity: High. The popularity score combines profile views, clicks and the number of times …See details»
Recommended Stories - Yahoo Finance
Mar 29, 2021 Media Contact:Gina NugentTen Bridge [email protected] Investor Contact:Michael Gray617-835 …See details»
Imara Announces Opening of Higher Dose Arms in Global Phase
Mar 17, 2021 For more information, please visit www.imaratx.com. Cautionary Note Regarding Forward-Looking Statements. Statements in this press release about future expectations, …See details»
Imara to Report Data Demonstrating the Potential of Tovinontrine …
Nov 8, 2021 Preclinical data from three different mouse models of HFpEF to be presented at American Heart Association (AHA) Scientific Sessions HFpEF development to be led by …See details»